Risk factors

Biopharmaceutical development risks dominate, focusing on clinical trial success for azetukalner, regulatory approvals by FDA and EMA, and financing needs.

Clinical-stage biopharmaceutical operations rely heavily on the proprietary XmAb technology platform and partnerships. Significant ongoing operating losses and heavy reliance on external financing dictate the business trajectory.

Technology evolution, competition, and monetization strategies dominate Xperi's risk profile. Royalty dependency, advertising revenue risks, and international operations shape financial exposure. Complex distribution, platform dependencies, and evolving data privacy regulations create operational uncertainties.

Operating across 150 countries with two-thirds of sales outside the US exposes Dentsply Sirona to global supply chain, currency, and regulatory volatility. Restructuring under the 2024 Plan targets a 2% to 4% global workforce reduction while addressing ongoing regulatory uncertainties from halting new Byte aligner patients. Complex medical device regulations, including FDA and EU MDR requirements, present significant compliance hurdles and potential delays in product commercialization.

Zai Lab's risk profile is heavily dominated by operational, legal, and political dependencies in mainland China, including government intervention, currency controls, and complex regulatory compliance.

Payment processing and financial products expose Toast to fraud, counterparty, network-rule, and customer-credit risks.

AI export controls and proposed AI Diffusion rules could restrict sales of NVIDIA chips, software, and systems worldwide.

Client cash balances, interest rates, and securities values directly drive Schwab’s revenue, profitability, and client confidence.

U.S. defense funding, contracting, and customer concentration dominate the risk section.

CTV growth, seller adoption, and access to premium inventory are central to Magnite’s growth prospects.

Teva launched a generic Korlym in January 2024 after a court found it would not infringe Corcept’s asserted patents.

International operations dominate: 70% of 2024 revenue came from outside the U.S., across 100-plus customer countries.